Watertown biotech Selecta halts cancer drug trial after patient dies

Selecta Biosciences has halted a small trial of one of its cancer drugs after the death of one participant, sending shares of the Watertown biotech down. Selecta (Nasdaq: SELB) said it had halted a Phase 1 trial of its cancer drug candidate SEL-403 this week after reporting problems with two of the four participants. One patient died after developing pneumonitis, while a second developed a potentially life-threatening buildup of fluid around the he art, Selecta disclosed after markets closed Wednesday. Investigators…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news